Immunologic correlates in the course of treatment with immunomodulating antibodies

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Monoclonal antibodies targeting immune checkpoints (e.g., CTLA-4, PD-1) are established treatments for metastatic melanoma and emerging for other cancers.
• A significant portion of patients do not achieve clinical benefit from these immunotherapies.
• The need for precise mechanisms of action, biomarker discovery, and management of immune-related side effects and costs is critical.

Purpose of the Study:

• To review and categorize immunologic correlates of immune checkpoint inhibitor therapy.
• To discuss the utility of various biomarkers, including pharmacodynamic changes, surrogate markers, and predictive markers for response and adverse events.
• To explore the integration of these biomarkers into clinical practice and future research directions.

Main Methods:

• Review of existing literature on immunologic correlates associated with immune checkpoint inhibitor therapy.
• Analysis of data from serum, peripheral blood immune cell subsets, and tumor-infiltrating lymphocytes.
• Discussion of prospective validation and clinical integration strategies for biomarkers.

Main Results:

• Identified different classes of immunologic correlates: pharmacodynamic changes, response correlates (surrogate markers), and predictive markers for response and immune-related adverse events.
• Summarized data on correlates analyzed in serum, peripheral blood immune cells, and tumor-infiltrating lymphocytes.
• Highlighted the importance of these correlates in understanding treatment efficacy and toxicity.

Conclusions:

• Immunologic correlates are crucial for understanding the efficacy and limitations of immune checkpoint inhibitors.
• Biomarker discovery and validation are essential for personalizing cancer treatment and improving patient outcomes.
• Future research should focus on prospective validation and integration of biomarkers into routine clinical practice.